

Exploring Drugs Targeting Peripheral Nerve Paralysis
Abstract
Peripheral nerve paralysis, condition manifested by the impaired fucation of nerves outside the central nervous system, poses more challenges to patients and health care professionals. Corticosteroids , namely prednisone, are generally prescribed to decrease inflammation and mitigate the immune response that may result in nerve damage. These drugs assist alleviate symptoms and increase the recovery particularly of Peripheral nerves, especially CYP in cases of acute paralysis because of an inflammatory conditions. Nonsteroidal anti_ inflammatory drugs ( NSAIDs ), like ibuprofen, perform by reducing inflammation and providing pain relief. Neurotrophic factors are proteins that enhance the survival. Development and function of neurons. Drugs targeting neuro tropic factors, namely nerve growth factor ( NGF ), aim to activate nerve regeneration and enhance the functional recovery of paralyzed Peripheral nerves. A very few anti convulsant drugs, namely gabapentin and pregabalin, have exhibited efficacy particularly in managing neuritropic pain related to Peripheral nerve paralysis. In a very few cases of Peripheral nerve paralysis with an immune component. Intra venous immunoglobulin ( IVIG ) therapy may be taken into consideration IVIG consists of antibodies that can modulate the immune response. Potentially decreasing inflammation and enhancing nerve recovery demyelination or damage to the protective myelin sheath surrounding nerve is a common feature particularly on Peripheral nerve disorders Drugs targeting myelin repair, namely certain experimental agents and remyelinating agents, aim to restore the integrity of the myelin sheath and increase nerve conduction. Peripheral nerve paralysis frequently involves impaired blood flow especially to the affected area, resulting in reduced oxygen and nutrient supply . Vasodilators, which dilate blood vessels, can enhance blood circulation and promote the healing and damaged nerves. Finally it is concluded that the pharmacological landscape for treating Peripheral nerve paralysis diverse, with drugs targeting many adverts of the condition, from Inflammation and pain into nerve regeneration and myelin repair.
References
Kurita GP, Sjøgren P, Klepstad P, Mercadante S. Interventional Techniques to Management of Cancer-Related Pain: Clinical and Critical Aspects. Cancers (Basel). 2019 Mar 29;11(4) [PMC free article] [PubMed]
Raj N. Regional anesthesia for sternotomy and bypass-Beyond the epidural. Paediatr Anaesth. 2019 May;29(5):519-529. [PubMed]
Donado C, Solodiuk J, Rangel SJ, Nelson CP, Heeney MM, Mahan ST, Ullrich C, Tsegaye B, Berde CB. Patient- and Nurse-Controlled Analgesia: 22-Year Experience in a Pediatric Hospital. Hosp Pediatr. 2019 Feb;9(2):129-133. [PubMed]
Saranteas T, Koliantzaki I, Savvidou O, Tsoumpa M, Eustathiou G, Kontogeorgakos V, Souvatzoglou R. Acute pain management in trauma: anatomy, ultrasound-guided peripheral nerve blocks and special considerations. Minerva Anestesiol. 2019 Jul;85(7):763-773. [PubMed]
Tran DQ, Salinas FV, Benzon HT, Neal JM. Lower extremity regional anesthesia: essentials of our current understanding. Reg Anesth Pain Med. 2019 Jan 11; [PubMed]
Refbacks
- There are currently no refbacks.